These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26358114)

  • 1. Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm.
    Masecchia S; Coco S; Barla A; Verri A; Tonini GP
    BMC Med Genomics; 2015 Sep; 8():57. PubMed ID: 26358114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
    Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R; Oberthuer A; Zapatka M; Brors B; Hero B; Ernestus K; Oestreich J; Fischer M; Simon T; Berthold F
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
    Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
    Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
    Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
    Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
    Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?
    Tonini GP
    BMC Cancer; 2017 Jan; 17(1):20. PubMed ID: 28056863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
    Breen CJ; O'Meara A; McDermott M; Mullarkey M; Stallings RL
    Cancer Genet Cytogenet; 2000 Jul; 120(1):44-9. PubMed ID: 10913676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
    Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
    Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
    Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic predisposition and chromosome instability in neuroblastoma.
    Tonini GP; Capasso M
    Cancer Metastasis Rev; 2020 Mar; 39(1):275-285. PubMed ID: 31927719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results.
    Combaret V; Iacono I; Bréjon S; Schleiermacher G; Pierron G; Couturier J; Bergeron C; Blay JY
    Cancer Genet; 2012 Dec; 205(12):657-64. PubMed ID: 23265803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
    Bénard J; Raguénez G; Kauffmann A; Valent A; Ripoche H; Joulin V; Job B; Danglot G; Cantais S; Robert T; Terrier-Lacombe MJ; Chassevent A; Koscielny S; Fischer M; Berthold F; Lipinski M; Tursz T; Dessen P; Lazar V; Valteau-Couanet D
    Mol Oncol; 2008 Oct; 2(3):261-71. PubMed ID: 19383347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
    Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.